Healthcare technology company Medtronic plc (NYSE:MDT) announced on Thursday that it has completed its separation of MiniMed Group Inc (Nasdaq:MMED).
Medtronic elected to exchange all of its remaining interest in MiniMed (a total of 252,813,348 shares of common stock) in its previously announced offer to exchange shares of MiniMed common stock for outstanding Medtronic ordinary shares, which was 5.4x subscribed.
"Today's separation marks an important milestone for both companies as each moves forward with a clear strategic focus," said Geoff Martha, Medtronic chairman and CEO. "For Medtronic, that means putting the full weight of our organisation behind advancing innovation and fueling growth across our Cardiovascular, Neuroscience and Surgical portfolios."
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease
Lilly to acquire Merida Biosciences in USD2.875bn deal
GE HealthCare expands Vivid cardiovascular ultrasound portfolio with three new systems
Daiichi Sankyo data highlight real-world impact of bempedoic acid on cardiovascular risk
Revier Therapeutics closes EUR6m seed financing and launches operations
Tempus announces receipt of FDA clearance for AI pulmonary hypertension detection product
European Commission grants orphan designation for Lundbeck's asedebart
Hanmi Pharm enters exclusive licensing deal with Genentech for obesity therapy HM17321
Olio Labs reveals study demonstrating AI-driven in vivo platform can predict clinical trial outcomes
Mezzion Pharma Co reports positive results from new in vivo study of udenafil
Incyte's Opzelura approved in European Union for moderate atopic dermatitis
American Regent recalls one lot of Papaverine Hydrochloride Injection due to particulate matter